论文部分内容阅读
国家有关部门发表的权威资料表明:我国是病毒性肝炎的高发区,其中仅乙肝表面抗原阳性人数就约达1.2亿。目前,在我国感染乙肝、丙肝人数中约有3000万人逐步发展成慢性肝炎肝硬化甚至原发性肝癌,每年死于肝癌者约达13万人,每年全国此项医疗费用耗资达300-500亿元。研制病毒性肝炎的防治药物,解救病人痛苦,多年来成为世界和我国医学界的一大课题。
Authoritative data published by the relevant state departments show that: China is a high incidence of viral hepatitis, of which only hepatitis B surface antigen-positive number of about 120 million. At present, about 30 million people in our country have been infected with hepatitis B and hepatitis C, and about 30 million people have gradually developed into chronic liver cirrhosis or even primary liver cancer. Each year, about 130,000 people die of liver cancer. The annual national cost of this medical service is 300-500 100 million yuan. The development of viral hepatitis prevention and treatment of drugs, the rescue of patients suffering, over the years has become the world and China’s medical community a major issue.